Finepoint Capital LP
- SEC CIK
- 0001608126
- Latest filing
- Aug 13, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 13, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 25
- −1 vs. Q1 2024
- Portfolio value
- $352.3M
- −$37.7M (−9.7%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| LBRDKLiberty Broadband Corp | COM SER C | 1,994,510 | $109.3M | 31.0% | +108,250+5.7% | Added | History |
| RVMDRevolution Medicines, Inc. | COM | 729,464 | $28.3M | 8.0% | +52,364+7.7% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 189,272 | $25.8M | 7.3% | +13,600+7.7% | Added | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 638,352 | $24.0M | 6.8% | +45,824+7.7% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 54,028 | $23.2M | 6.6% | +4,028+8.1% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 132,835 | $21.0M | 6.0% | −25,622−16.2% | Reduced | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 388,835 | $17.1M | 4.9% | +27,919+7.7% | Added | History |
| ARVNArvinas, Inc. | COM | 574,378 | $15.3M | 4.3% | +35,278+6.5% | Added | History |
| ACADAcadia Pharmaceuticals Inc | COM | 905,384 | $14.7M | 4.2% | +64,931+7.7% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,776,728 | $14.6M | 4.1% | +127,507+7.7% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 256,449 | $13.9M | 3.9% | +18,403+7.7% | Added | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 542,762 | $13.4M | 3.8% | +39,003+7.7% | Added | History |
| RLAYRelay Therapeutics, Inc. | COM | 1,605,346 | $10.5M | 3.0% | +115,176+7.7% | Added | History |
| PRTAProthena Corp Public Ltd Co | SHS | 433,471 | $8.95M | 2.5% | +31,071+7.7% | Added | History |
| EYPTEyePoint, Inc. | COM NEW | 707,404 | $6.15M | 1.7% | +50,804+7.7% | Added | History |
| SLDBSolid Biosciences Inc. | COM NEW | 961,251 | $5.45M | 1.5% | 00.0% | Unchanged | History |
| Churchill Capital Corp VII17144M110 | *W EXP 02/29/202 | 548,000 | $191.8K | 0.1% | 00.0% | Unchanged | – |
| MNYWWMoneyHero Ltd | *W EXP 09/13/202 | 895,000 | $71.6K | <0.1% | 00.0% | Unchanged | History |
| CNDAWConcord Acquisition Corp II | *W EXP 99/99/999 | 408,333 | $44.9K | <0.1% | 00.0% | Unchanged | History |
| Swiftmerge Acquisition CorpG63836111 | *W EXP 12/13/202 | 490,000 | $39.2K | <0.1% | 00.0% | Unchanged | – |
| Ys Biopharma Co LtdG9845F117 | *W EXP 03/15/202 | 489,999 | $33.4K | <0.1% | 00.0% | Unchanged | – |
| CLDWWCalidi Biotherapeutics, Inc. | *W EXP 03/14/202 | 655,200 | $27.6K | <0.1% | 00.0% | Unchanged | History |
| Compass Digital Acquisitn CoG2476C123 | *W EXP 09/29/202 | 459,906 | $27.5K | <0.1% | 00.0% | Unchanged | – |
| Marblegate Acquisition Corp.56608A113 | *W EXP 08/31/202 | 735,000 | $26.8K | <0.1% | 00.0% | Unchanged | – |
| CLDICalidi Biotherapeutics, Inc. | CL A | 125,000 | $25.0K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q1 2024 (1)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| DISH Network CORP25470MAF6 | NOTE 12/1 | – | $13.5M | 3.4% | – |